Tracleer bosentan regulatory update

U.K.'s NICE issued an initial technology appraisal for 5 drugs indicated to treat pulmonary arterial hypertension (PAH), including Flolan epoprostenol from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); Ventavis iloprost from Bayer AG (FSE:BAY, Leverkusen, Germany); Tracleer bosentan from Actelion; Thelin sitaxentan from Encysive Pharmaceuticals Inc. (NASDAQ: ...